Mal-PEG2-VCP-Eribulin 

Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates^[1][2][3].

1374.57

C₇₀H₉₉N₇O₂₁

2130869-18-8

固体

White to off-white

Room temperature in continental US; may vary elsewhere.

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

• [1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.

  [2]. Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505.  [Content Brief]

  [3]. Watanabe K, et al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4;10(2):161-174.  [Content Brief]